102,828 Shares in CeriBell (NASDAQ:CBLL) Acquired by Northern Trust Corp

Northern Trust Corp acquired a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 102,828 shares of the company's stock, valued at approximately $2,661,000. Northern Trust Corp owned about 0.29% of CeriBell at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CBLL. FMR LLC acquired a new stake in CeriBell during the fourth quarter worth about $128,120,000. Vanguard Group Inc. acquired a new stake in shares of CeriBell during the fourth quarter valued at about $18,015,000. Board of Trustees of The Leland Stanford Junior University acquired a new stake in shares of CeriBell during the fourth quarter valued at about $16,143,000. Franklin Resources Inc. acquired a new stake in shares of CeriBell during the fourth quarter valued at about $12,460,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of CeriBell during the fourth quarter valued at about $10,750,000.

CeriBell Trading Down 1.0%

Shares of NASDAQ CBLL traded down $0.17 during midday trading on Thursday, hitting $17.02. The company's stock had a trading volume of 238,637 shares, compared to its average volume of 280,432. The business's fifty day simple moving average is $16.86 and its two-hundred day simple moving average is $21.84. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.49 million during the quarter, compared to analysts' expectations of $19.30 million. Equities research analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Activity

In other news, CEO Xingjuan Chao sold 5,700 shares of the firm's stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the transaction, the chief executive officer now owns 746,451 shares of the company's stock, valued at approximately $11,211,694.02. This trade represents a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders sold 49,700 shares of company stock valued at $796,434. 20.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CBLL. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price target for the company. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.